Literature DB >> 28890808

The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice.

Marwan Fakih1.   

Abstract

Year:  2017        PMID： 28890808      PMCID： PMC5582034          DOI： 10.21037/jgo.2017.07.08

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


× No keyword cloud information.
  12 in total

1.  Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.

Authors:  Daniel G Haller; Josep Tabernero; Jean Maroun; Filippo de Braud; Timothy Price; Eric Van Cutsem; Mark Hill; Frank Gilberg; Karen Rittweger; Hans-Joachim Schmoll
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

2.  Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.

Authors:  Daniel G Haller; Paul J Catalano; John S Macdonald; Mark A O'Rourke; Michael S Frontiera; Don V Jackson; Robert J Mayer
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

3.  Capecitabine as adjuvant treatment for stage III colon cancer.

Authors:  Chris Twelves; Alfred Wong; Marek P Nowacki; Markus Abt; Howard Burris; Alfredo Carrato; Jim Cassidy; Andrés Cervantes; Jan Fagerberg; Vassilis Georgoulias; Fares Husseini; Duncan Jodrell; Piotr Koralewski; Hendrik Kröning; Jean Maroun; Norbert Marschner; Joseph McKendrick; Marek Pawlicki; Riccardo Rosso; Johannes Schüller; Jean-François Seitz; Borut Stabuc; Jerzy Tujakowski; Guy Van Hazel; Jerzy Zaluski; Werner Scheithauer
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

4.  A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.

Authors:  I Chau; A R Norman; D Cunningham; D Tait; P J Ross; T Iveson; M Hill; T Hickish; F Lofts; D Jodrell; A Webb; J R Oates
Journal:  Ann Oncol       Date:  2005-02-02       Impact factor: 32.976

5.  Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.

Authors:  Stephanie R Land; Jacek A Kopec; Reena S Cecchini; Patricia A Ganz; H Samuel Wieand; Linda H Colangelo; Kate Murphy; J Philip Kuebler; Thomas E Seay; Burton M Needles; James D Bearden; Lauren K Colman; Keith S Lanier; Eduardo R Pajon; David Cella; Roy E Smith; Michael J O'Connell; Joseph P Costantino; Norman Wolmark
Journal:  J Clin Oncol       Date:  2007-04-30       Impact factor: 44.544

6.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

Authors:  J Philip Kuebler; H Samuel Wieand; Michael J O'Connell; Roy E Smith; Linda H Colangelo; Greg Yothers; Nicholas J Petrelli; Michael P Findlay; Thomas E Seay; James N Atkins; John L Zapas; J Wendall Goodwin; Louis Fehrenbacher; Ramesh K Ramanathan; Barbara A Conley; Patrick J Flynn; Gamini Soori; Lauren K Colman; Edward A Levine; Keith S Lanier; Norman Wolmark
Journal:  J Clin Oncol       Date:  2007-04-30       Impact factor: 44.544

7.  Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

Authors:  Thierry Andre; Philippe Colin; Christophe Louvet; Erik Gamelin; Olivier Bouche; Emmanuel Achille; Nicolas Colbert; Catherine Boaziz; Pascal Piedbois; Nicole Tubiana-Mathieu; Arnaud Boutan-Laroze; Michel Flesch; Marc Buyse; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2003-08-01       Impact factor: 44.544

8.  Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.

Authors:  Hendrik-Tobias Arkenau; Dirk Arnold; Jim Cassidy; Eduardo Diaz-Rubio; Jean-Yves Douillard; Howard Hochster; Andrea Martoni; Axel Grothey; Axel Hinke; Wolff Schmiegel; Hans-Joachim Schmoll; Rainer Porschen
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

9.  Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.

Authors:  Howard S Hochster; Lowell L Hart; Ramesh K Ramanathan; Barrett H Childs; John D Hainsworth; Allen L Cohn; Lucas Wong; Louis Fehrenbacher; Yousif Abubakr; M Wasif Saif; Lee Schwartzberg; Eric Hedrick
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

10.  Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.

Authors:  Dimitrios Pectasides; Vasilios Karavasilis; George Papaxoinis; Georgia Gourgioti; Thomas Makatsoris; Georgia Raptou; Eleni Vrettou; Joseph Sgouros; Epaminontas Samantas; George Basdanis; Pavlos Papakostas; Dimitrios Bafaloukos; Vassiliki Kotoula; Haralambos P Kalofonos; Chrisoula D Scopa; George Pentheroudakis; George Fountzilas
Journal:  BMC Cancer       Date:  2015-05-10       Impact factor: 4.430
View more
  1 in total

1.  Reg4 and its downstream transcriptional activator CD44ICD in stage II and III colorectal cancer.

Authors:  Jared A Sninsky; Kumar S Bishnupuri; Iván González; Nikolaos A Trikalinos; Ling Chen; Brian K Dieckgraefe
Journal:  Oncotarget       Date:  2021-02-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.